Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $5.3 million.

  • Puma Biotechnology's Change in Accured Expenses fell 54.72% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.5 million, marking a year-over-year decrease of 245.45%. This contributed to the annual value of -$15.8 million for FY2024, which is 108.66% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Change in Accured Expenses is $5.3 million, which was up 8.09% from $4.9 million recorded in Q2 2025.
  • Puma Biotechnology's Change in Accured Expenses' 5-year high stood at $22.2 million during Q3 2021, with a 5-year trough of -$30.9 million in Q1 2022.
  • Over the past 3 years, Puma Biotechnology's median Change in Accured Expenses value was $1.3 million (recorded in 2024), while the average stood at -$2.1 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 4,182.08% in 2021, then spiked by 1,283.49% in 2022.
  • Puma Biotechnology's Change in Accured Expenses (Quarterly) stood at $1.5 million in 2021, then skyrocketed by 1,283.49% to $20.7 million in 2022, then plummeted by 45.26% to $11.3 million in 2023, then plummeted by 221.48% to -$13.8 million in 2024, then tumbled by 54.72% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $4.9 million for Q2 2025, and -$9.9 million during Q1 2025.